title: Efficacy of a pedometer-based physical activity program on parameters of diabetes control in type 2 diabetes mellitus.
abstract: The aim of the study was to determine whether a recommendation to walk 10000 steps per day would result in significant improvements in glycemic control, insulin sensitivity, and cardiovascular risk in patients with type 2 diabetes mellitus. The study was a 6-week randomized controlled trial that included 30 patients with type 2 diabetes mellitus. After 10 days of baseline activity, patients were randomized into 2 groups: control and active. The control group (n = 15) was instructed to continue with their baseline activity for 6 weeks. The active group (n = 15) was instructed to walk at least 10000 steps per day 5 or more days per week, for 6 weeks. Data relevant to glycemic control and other parameters of health were collected at study weeks 0 and 6. There were no differences in the baseline activity between groups (P = .36). Subjects in the active group significantly increased physical activity by 69% during the intervention phase of the study (P = .002), whereas there was no change in the physical activity of the control group (P > .05). High-density lipoprotein cholesterol and resting energy expenditure significantly increased in the active group (P < .05). Finally, plasminogen activator inhibitor 1 (PAI-1) activity was reduced by exercise relative to the control group (P = .03). There were no differences in any other study parameters during the 6-week study. In conclusion, short-term intervention with a pedometer increased physical activity and positively affected plasminogen activator inhibitor 1 activity in previously inactive patients with type 2 diabetes mellitus. The use of a pedometer may prove to be an effective tool for promoting healthy lifestyle changes that include daily physical activity and self-monitoring of therapeutic goals.
authors.affiliation: School of Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Araiza
authors.forename: Hilary
authors.initials: H
authors.lastname: Hewes
authors.forename: Carrie
authors.initials: C
authors.lastname: Gashetewa
authors.forename: Chantal A
authors.initials: CA
authors.lastname: Vella
authors.forename: Mark R
authors.initials: MR
authors.lastname: Burge
mesh_terms: D000328:Adult; D000368:Aged; D000886:Anthropometry; D001823:Body Composition; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000453:epidemiology; D008076:Cholesterol, HDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000628:therapy*; D015444:Exercise / Q000502:physiology*; D005081:Exercise Therapy / Q000295:instrumentation*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008019:Life Style; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000502:physiology*; D018384:Oxidative Stress / Q000502:physiology; D010349:Patient Compliance; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D012307:Risk Factors
chemical_list: D008076:Cholesterol, HDL; D006442:Glycated Hemoglobin; D008055:Lipids; D017395:Plasminogen Activator Inhibitor 1